ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Blueprint Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT
March 09, 2021Blueprint Medicines announced the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of advanced systemic mastocytosis (SM). -
Blueprint eyes quick filing for GIST drug avapritinib
December 13, 2018Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set it on course for regulatory filings – and a close race to market with rival Deciphera. -
Blueprint Announces Updated Results from Ongoing Avapritinib Trial
December 04, 2018Blueprint Medicines announced updated results for the Phase 1 EXPLORER clinical trial of avapritinib, a potent and highly selective inhibitor of D816V mutant KIT.....
Pharma Sources Insight January 2025
